Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]FLT-PET for Prediction of Response to Regorafenib in mCRC
NCT02175095Completed
- Sponsor
- Asan Medical Center
- Start
- Jul 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of regorafenib in metastatic colorectal cancer (mCRC), sponsored by Asan Medical Center. Primary endpoints: Assessment of Early Response by 18F-Fluorodeoxyglucose (18F-FDG) PET/CT Compared With CT RECIST at 8 weeks, Assessment of Early Response by 3'-Deoxy-3'-18F-fluorothymidine (18F-FLT) PET/CT Compared With CT RECIST at 8 weeks and 1 more. Started Jul 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02175095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02175095.